| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2564 | 2010 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 706 | 2009 |
| Management of cancer pain: ESMO clinical practice guidelines CI Ripamonti, D Santini, E Maranzano, M Berti, F Roila Annals of oncology 23, vii139-vii154, 2012 | 658 | 2012 |
| Tissue invasion and metastasis: Molecular, biological and clinical perspectives WG Jiang, AJ Sanders, M Katoh, H Ungefroren, F Gieseler, M Prince, ... Seminars in cancer biology 35, S244-S275, 2015 | 565 | 2015 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... J Clin Oncol 27 (16), 2622-2629, 2009 | 506 | 2009 |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ... Clinical Cancer Research 9 (8), 2893-2897, 2003 | 469 | 2003 |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 456 | 2015 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 379 | 2007 |
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ... Clinical Cancer Research 8 (5), 1080-1084, 2002 | 355 | 2002 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 346 | 2019 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 331 | 2019 |
| Bone health in cancer: ESMO clinical practice guidelines R Coleman, P Hadji, JJ Body, D Santini, E Chow, E Terpos, S Oudard, ... Annals of oncology 31 (12), 1650-1663, 2020 | 312 | 2020 |
| High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 305 | 2008 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 302 | 2015 |
| Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ... European journal of cancer 44 (13), 1875-1882, 2008 | 258 | 2008 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 255 | 2020 |
| Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis FR Bertani, P Mozetic, M Fioramonti, M Iuliani, G Ribelli, F Pantano, ... Scientific reports 7 (1), 8965, 2017 | 230 | 2017 |
| Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ... Annals of Oncology 23 (9), 2313-2318, 2012 | 221 | 2012 |
| Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in … D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ... Clinical Cancer Research 13 (15), 4482-4486, 2007 | 220 | 2007 |
| The antineoplastic role of bisphosphonates: from basic research to clinical evidence D Santini, UV Gentilucci, B Vincenzi, A Picardi, F Vasaturo, A La Cesa, ... Annals of Oncology 14 (10), 1468-1476, 2003 | 220 | 2003 |
